Quick Search

 

 


 

 

Home > Protocol Summaries: Compounds > Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine > Protocol Summary for 107924

Protocol Summary for 107924

Protocol Summary
Protocol Id: 107924
Secondary Ids:
Title: Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix) when administered to healthy chinese children 6-8 years of age.
Phase: phase 3
Acronym:
FDA Regulated Intervention?:
Section 801 Clinical Trial?:
Delayed Posting:
IND/IDE Protocol?: no
Study Type: Interventional
Oversight Authority:
  • China: State Food and Drug Administration
Collaborators:
Brief Summary:
Detailed Description:
Record Verification Date: July 2010
Status: Completed
Why Study Stopped:
Study Start Date: January 2007
Study Completion Date:
Study Completion Date Type:
Primary Completion Date:
Primary Completion Date Type:
Primary Purpose: prevention
Allocation: Non-randomized
Masking: Open Label
Masked Subject: no
Masked Caregiver: no
Masked Investigator: no
Masked Assessor: no
Study Design (Assignment): Single Group Assignment
Study Classification (Endpoint): Safety Study
Primary Outcomes:
  • Occurrence of solicited symptoms during 4 days following vaccination, unsolicited symptoms during the 31 days following vaccination and serious adverse events
Secondary Outcomes:
Conditions:
  • Diphtheria
  • Tetanus
  • Pertussis
Keywords:
  • uncontrolled
Eligibility Criteria: Click to view inclusion/exclusion criteria
Gender: Both
Minimum Age: 6 Year
Maximum Age: 8 Year
Enrollment: 30
Enrollment Type:
Healthy Volunteers?: yes
Central Contact: US GSK Clinical Trials Call Center
Central Contact Phone: 877-379-3718
Central Contact Email:
Backup Central Contact:
Backup Central Contact Phone:
Backup Central Contact Email:
Overall Study Official: GSK Clinical Trials
Overall Study Official Affiliation: GlaxoSmithKline
Overall Study Official Role: Study Director
Responsible Party Name/Official Title: Cheri Hudson; Clinical Disclosure Advisor
Responsible Party Organization: GSK Clinical Disclosure
Location and Contact Information: Click to view location information